504 POSTER GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in Non-Hodgkin lymphoma xenograft models and superior B cell depletion

Autor:	J. Dal Porto, Adam Nopora, P. Umana, Roger Grau, Sabine Bauer, Frank Herting, Christian Gerdes, Christian Klein, E. Moessner, Thomas Friess
Rok vydání:	2008
Předmět:	CD20 Antitumor activity Cancer Research biology business.industry Epitope B cell depletion Oncology Immunology biology.protein Hodgkin lymphoma Medicine Antibody business
Zdroj:	European Journal of Cancer Supplements. 6:160
ISSN:	1359-6349
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5548c77881b116445d962f5eb471af42 https://doi.org/10.1016/s1359-6349(08)72438-8 Zobrazit plný text záznamu Full Text from ScienceDirect